adebrelimab + famitinib + fluzoparib + apatinib

This therapeutic regimen is a precision medicine neoadjuvant strategy for patients with early-stage or locally advanced HR+/HER2- breast cancer, developed in the context of the SNF (Surface, Nucleus, Fibroblast) classification system. The regimen involves the selective addition of targeted agents to a chemotherapy backbone (weekly nab-paclitaxel followed by epirubicin and cyclophosphamide) based on the patient's specific SNF subtype. **Adebrelimab** is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses. **Famitinib** is a multi-targeted tyrosine kinase inhibitor (TKI) primarily inhibiting VEGFR2, PDGFR, and c-Kit. **Fluzoparib** is a PARP1/2 inhibitor that exploits DNA repair deficiencies. **Apatinib** is a selective small-molecule TKI targeting VEGFR2 to inhibit angiogenesis. In this Phase III trial, SNF2 subtype patients receive adebrelimab and famitinib, SNF3 patients receive fluzoparib, and SNF4 patients receive apatinib.

Brand names

AiruikaAiTan

Other names

adebrelimab + famitinib + fluzoparib + apatinib-Fudan University-breast cancer (HR+/HER2-)